Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals

Ajay Wanchu, S. Arora, A. Bhatnagar, A. Sud, P. Bambery, S. Singh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pentoxiphylline, an inhibitor of tumor necrosis factor-α (TNF-α) has been used in the treatment of human immunodeficiency virus (HIV) infection. The inhibition of TNF-α results in decreased immune activation. Beta2 microglobulin (β2M) has been used as a surrogate marker to study the progression of HIV infection. The objective of this study was to see if use of pentoxiphylline resulted in any decline in β2M levels. Twenty patients with HIV infection who were free of opportunistic infections at the time of inclusion in the study and 18 age and sex matched controls were studied. β2M was measured using an enzyme immunoassay before and four weeks after the start of treatment with pentoxiphylline. Mean levels of β2M before therapy were 1.51 ± 0.77 mg/l (range 0.78 - 3.8 mg/l) and were significantly higher (P <0.001) than the levels among controls [0.72 ± 0.06 mg/l (range 0.46 - 0.88 mg/l)]. β2M levels in patients declined to 0.85 ± 0.22 mg/l (range 0.72 - 1.0 mg/l) after four weeks of therapy and this was statistically significant (P <0.001). Use of pentoxiphylline for four weeks results in a significant decline in the levels of β2M suggesting that the level of immune activation is reduced with the therapy.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalIndian Journal of Medical Research
Volume113
Issue numberMAR.
StatePublished - 2001
Externally publishedYes

Fingerprint

Viruses
HIV
Virus Diseases
Tumor Necrosis Factor-alpha
Chemical activation
Level control
Therapeutics
Opportunistic Infections
Immunoenzyme Techniques
Enzymes
Biomarkers

Keywords

  • Beta microglobulin
  • Enzyme immunoassay
  • HIV infection
  • Immune activation
  • Pentoxiphyllinet-tumor necrosis factor-α

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wanchu, A., Arora, S., Bhatnagar, A., Sud, A., Bambery, P., & Singh, S. (2001). Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals. Indian Journal of Medical Research, 113(MAR.), 75-77.

Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals. / Wanchu, Ajay; Arora, S.; Bhatnagar, A.; Sud, A.; Bambery, P.; Singh, S.

In: Indian Journal of Medical Research, Vol. 113, No. MAR., 2001, p. 75-77.

Research output: Contribution to journalArticle

Wanchu, A, Arora, S, Bhatnagar, A, Sud, A, Bambery, P & Singh, S 2001, 'Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals', Indian Journal of Medical Research, vol. 113, no. MAR., pp. 75-77.
Wanchu, Ajay ; Arora, S. ; Bhatnagar, A. ; Sud, A. ; Bambery, P. ; Singh, S. / Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals. In: Indian Journal of Medical Research. 2001 ; Vol. 113, No. MAR. pp. 75-77.
@article{eb6fd1afe9454f18bbfa582226443090,
title = "Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals",
abstract = "Pentoxiphylline, an inhibitor of tumor necrosis factor-α (TNF-α) has been used in the treatment of human immunodeficiency virus (HIV) infection. The inhibition of TNF-α results in decreased immune activation. Beta2 microglobulin (β2M) has been used as a surrogate marker to study the progression of HIV infection. The objective of this study was to see if use of pentoxiphylline resulted in any decline in β2M levels. Twenty patients with HIV infection who were free of opportunistic infections at the time of inclusion in the study and 18 age and sex matched controls were studied. β2M was measured using an enzyme immunoassay before and four weeks after the start of treatment with pentoxiphylline. Mean levels of β2M before therapy were 1.51 ± 0.77 mg/l (range 0.78 - 3.8 mg/l) and were significantly higher (P <0.001) than the levels among controls [0.72 ± 0.06 mg/l (range 0.46 - 0.88 mg/l)]. β2M levels in patients declined to 0.85 ± 0.22 mg/l (range 0.72 - 1.0 mg/l) after four weeks of therapy and this was statistically significant (P <0.001). Use of pentoxiphylline for four weeks results in a significant decline in the levels of β2M suggesting that the level of immune activation is reduced with the therapy.",
keywords = "Beta microglobulin, Enzyme immunoassay, HIV infection, Immune activation, Pentoxiphyllinet-tumor necrosis factor-α",
author = "Ajay Wanchu and S. Arora and A. Bhatnagar and A. Sud and P. Bambery and S. Singh",
year = "2001",
language = "English (US)",
volume = "113",
pages = "75--77",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "MAR.",

}

TY - JOUR

T1 - Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals

AU - Wanchu, Ajay

AU - Arora, S.

AU - Bhatnagar, A.

AU - Sud, A.

AU - Bambery, P.

AU - Singh, S.

PY - 2001

Y1 - 2001

N2 - Pentoxiphylline, an inhibitor of tumor necrosis factor-α (TNF-α) has been used in the treatment of human immunodeficiency virus (HIV) infection. The inhibition of TNF-α results in decreased immune activation. Beta2 microglobulin (β2M) has been used as a surrogate marker to study the progression of HIV infection. The objective of this study was to see if use of pentoxiphylline resulted in any decline in β2M levels. Twenty patients with HIV infection who were free of opportunistic infections at the time of inclusion in the study and 18 age and sex matched controls were studied. β2M was measured using an enzyme immunoassay before and four weeks after the start of treatment with pentoxiphylline. Mean levels of β2M before therapy were 1.51 ± 0.77 mg/l (range 0.78 - 3.8 mg/l) and were significantly higher (P <0.001) than the levels among controls [0.72 ± 0.06 mg/l (range 0.46 - 0.88 mg/l)]. β2M levels in patients declined to 0.85 ± 0.22 mg/l (range 0.72 - 1.0 mg/l) after four weeks of therapy and this was statistically significant (P <0.001). Use of pentoxiphylline for four weeks results in a significant decline in the levels of β2M suggesting that the level of immune activation is reduced with the therapy.

AB - Pentoxiphylline, an inhibitor of tumor necrosis factor-α (TNF-α) has been used in the treatment of human immunodeficiency virus (HIV) infection. The inhibition of TNF-α results in decreased immune activation. Beta2 microglobulin (β2M) has been used as a surrogate marker to study the progression of HIV infection. The objective of this study was to see if use of pentoxiphylline resulted in any decline in β2M levels. Twenty patients with HIV infection who were free of opportunistic infections at the time of inclusion in the study and 18 age and sex matched controls were studied. β2M was measured using an enzyme immunoassay before and four weeks after the start of treatment with pentoxiphylline. Mean levels of β2M before therapy were 1.51 ± 0.77 mg/l (range 0.78 - 3.8 mg/l) and were significantly higher (P <0.001) than the levels among controls [0.72 ± 0.06 mg/l (range 0.46 - 0.88 mg/l)]. β2M levels in patients declined to 0.85 ± 0.22 mg/l (range 0.72 - 1.0 mg/l) after four weeks of therapy and this was statistically significant (P <0.001). Use of pentoxiphylline for four weeks results in a significant decline in the levels of β2M suggesting that the level of immune activation is reduced with the therapy.

KW - Beta microglobulin

KW - Enzyme immunoassay

KW - HIV infection

KW - Immune activation

KW - Pentoxiphyllinet-tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=0034909275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909275&partnerID=8YFLogxK

M3 - Article

C2 - 11525154

AN - SCOPUS:0034909275

VL - 113

SP - 75

EP - 77

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - MAR.

ER -